Quarterly report pursuant to Section 13 or 15(d)

Acquisitions, Investments, and Licenses - Schedule of Purchase Price Allocation (Details)

v3.3.0.814
Acquisitions, Investments, and Licenses - Schedule of Purchase Price Allocation (Details) - USD ($)
$ in Thousands
Aug. 20, 2015
May. 05, 2015
Sep. 30, 2015
Dec. 31, 2014
[1]
Business Acquisition [Line Items]        
Goodwill     $ 761,234 $ 224,292
Bio-Reference        
Business Acquisition [Line Items]        
Value of OPKO Common Stock issued to Bio-Reference shareholders $ 947,889      
Common stock value 2,259      
Less: Equity issuance costs (138)      
Cash paid at closing date 950,010      
Cash and cash equivalents 15,800      
Accounts receivable 162,940      
Inventory 19,825      
Other current assets, principally deferred tax assets 54,141      
Current assets 252,706      
Property, plant and equipment 106,306      
Intangible assets 549,800      
Goodwill 472,751      
Investments 5,326      
Other assets 12,164      
Total assets 1,399,053      
Accounts payable (79,360)      
Accrued expenses (29,249)      
Income taxes payable (20,411)      
Lines of credit and notes payable (65,701)      
Capital lease obligations (18,293)      
Deferred tax liability (non-current) (236,029)      
Total purchase price 950,010      
EirGen        
Business Acquisition [Line Items]        
Common stock value   $ 33,600    
Cash paid at closing date   100,200    
Cash and cash equivalents   5,500    
Accounts receivable   2,700    
Inventory   2,200    
Other current assets, principally deferred tax assets   1,400    
Current assets [2]   11,795    
Property, plant and equipment   8,117    
Intangible assets   57,671    
Goodwill   66,823    
Other assets   1,232    
Accounts payable and other liabilities   (6,254)    
Deferred tax liability (non-current)   (5,618)    
Total purchase price   133,766    
Trade names | Bio-Reference        
Business Acquisition [Line Items]        
Intangible assets 47,100      
IPR&D assets | EirGen        
Business Acquisition [Line Items]        
Intangible assets   19,597    
Customer relationships | Bio-Reference        
Business Acquisition [Line Items]        
Intangible assets 395,200      
Customer relationships | EirGen        
Business Acquisition [Line Items]        
Intangible assets   34,155    
Technology | Bio-Reference        
Business Acquisition [Line Items]        
Intangible assets 100,600      
Currently marketed products | EirGen        
Business Acquisition [Line Items]        
Intangible assets   $ 3,919    
Internally developed software | Bio-Reference        
Business Acquisition [Line Items]        
Intangible assets $ 6,900      
[1] As of December 31, 2014, total assets include $7.6 million and total liabilities include $12.1 million related to SciVac Ltd (“SciVac”). SciVac was a consolidated variable interest entity which we deconsolidated in July 2015. Refer to Note 5. SciVac’s consolidated assets were owned by SciVac and SciVac’s consolidated liabilities had no recourse against us.
[2] Current assets include cash, accounts receivable, inventory and other assets of $5.5 million, $2.7 million, $2.2 million and $1.4 million, respectively, related to the EirGen acquisition. The fair value of the accounts receivable equals the gross contractual amount at the date of acquisition.